Quiet Therapeutics
Anticancer Therapeutics Using Nanoparticles and Biomarkers
Company Overview
Snapshot
Founded in January 2010, Quiet Therapeutics operates with 1–10 employees. The company has raised a total of $18.5M across 3 funding rounds from 4 investors.
Business overview
Quiet Therapeutics is a cancer drug discovery and development company focused on creating a new generation of cancer therapeutics. The company utilizes its proprietary GAGomer technology to specifically target tumor cells with therapeutic nanoparticles. These nanoparticles are designed to target specific cancer cells that express a biomarker, delivering a therapeutic payload to induce cell death. This approach allows for flexibility in delivering medicines that can kill cancer cells, block protein production that promotes cancer, or leverage cancer cells' own machinery to produce therapeutic proteins. Quiet Therapeutics develops a diverse set of DNA, RNA, and small molecule anticancer therapeutics, operating within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals.
Strategic signal
In January 2015, Quiet Therapeutics was featured in an article highlighting its innovative approach to cancer treatment using nanoparticles. This signals the company's early recognition for its potential to revolutionize oncology through targeted drug delivery, emphasizing the strategic importance of its GAGomer technology in the broader pharmaceutical landscape.
Log in to access full profile ›Company Intelligence Q&A
- What is Quiet Therapeutics' core technology?
- Quiet Therapeutics develops anticancer therapeutics using its proprietary GAGomer technology, which involves nanoparticles and biomarkers to specifically target tumor cells.
- When was Quiet Therapeutics founded?
- Quiet Therapeutics was founded in January 2010.
- Which investors participated in Quiet Therapeutics' April 2015 funding round?
- In April 2015, Quiet Therapeutics secured funding from Jerusalem Global Ventures and Rainfall Ventures.
- Has Quiet Therapeutics received any non-equity funding?
- Yes, in November 2013, Quiet Therapeutics secured a grant from the European Union.